Source: Annual Congress 2012 - Tobacco cessation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. S. Valido Morales, P. Guerrero Zamora, A. Gomez Bastero Fernandez, C. Romero Muñoz, A. H. Vega Arias, V. Almadana Pacheo, T. Montemayor Rubio (Seville, Spain). Cardiovascular events related to the use of varenicline. Eur Respir J 2012; 40: Suppl. 56, 4040

Member's Comments

No comment yet.

Related content which might interest you: Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017 Use of varenicline in the treatment of smokers with cardiovascular disease Source: Annual Congress 2013 –Smoking cessation Year: 2013 Effectiveness of treatment with varenicline in smokers with cardiovascular diseases (CVD) Source: Annual Congress 2009 - Smoking cessation Year: 2009 Cardiovascular complications and norfenfluramine exposure with benfluorex use Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 Incident opioid drug use and adverse respiratory outcomes among older adults with COPD Source: Eur Respir J , 49 (3) 1602311; DOI: 10.1183/13993003.02311-2016 Year: 2017 Incident opioid drug use and adverse respiratory outcomes among older adults with COPD Source: Eur Respir J 2016; 48: 683-693 Year: 2016 Cardiovascular adverse effects during itraconazole therapy Source: Eur Respir J 2008; 32: 240 Year: 2008 A randomised controlled trial investigating the effects of varenicline on sympathovagal balance during acute nicotine withdrawal Source: International Congress 2014 – Three smoking-related diseases: cardiovascular, lung cancer and infection Year: 2014 Cardiovascular side-effects of common antibiotics Source: Eur Respir Monogr 2020; 88: 264-278 Year: 2020 Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Eur Respir J 2007; 30: Suppl. 51, 125s Year: 2007 QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Annual budgetary impact of varenicline as part of a smoking cessation strategy in Greece Source: International Congress 2015 – Emerging data on (e-)cigarettes and their health hazards Year: 2015 Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Late Breaking Abstract - Cardiovascular adverse events of drugs targeting IL-5 in severe asthma: a pharmacovigilance study Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020 Metrics of salbutamol use as predictors of future adverse outcomes in asthma Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Rates of major cardiovascular events in severe asthma: US real-world and clinical trial populations Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Adverse reactions to bupropion: fourteen cases reported in a French regional pharmacovigilance center. Impact on smoking withdrawal Source: Eur Respir J 2005; 26: Suppl. 49, 155s Year: 2005